What is the significance of Dysregulated Microglia and Dysfunctional Mitochondria in Neurodevelopmental, Psychiatric and Addiction Disorders?

Dysregulated **microglia–mitochondria** systems appear central to many brain disorders across development

Microglia (the brain's immune cells) and mitochondria (cellular "power plants") are deeply intertwined in shaping brain development, mood, cognition, and vulnerability to disease. Across neurodevelopmental, psychiatric, and addiction-related conditions, disrupted microglial function and mitochondrial dysfunction converge on **chronic neuroinflammation, abnormal synaptic wiring, and neuronal vulnerability**.

Roles in Neurodevelopmental Disorders (e.g., ASD, Schizophrenia)

Microglial sculpting of the developing brain
Microglia regulate neuronal survival, synaptic pruning, circuit wiring, blood–brain barrier formation, and neurogenesis. Dysregulated microglia can trigger neuroinflammation, synaptic abnormalities, and diminished neurogenesis, predisposing to neuropsychiatric disorders. (Zhu et al., 2023; Tay et al., 2018)Microglial dysfunction is specifically linked to ASD and schizophrenia, through altered synaptic pruning, neuroinflammation, and microbiota–microglia interactions. (Lukens & Eyo, 2022; Fan et al., 2023; Meng et al., 2024)**Microglial mitochondria in development**
Microglial mitochondrial metabolism directly supports phagocytosis and synaptic refinement; disruption of IL-33–ST2–AKT signaling impairs microglial mitochondrial activity, phagocytosis, and leads to synaptic and behavioral abnormalities, including seizure susceptibility. (He et al., 2021)Primary microglial complex I deficiency in mice causes microglial hypertrophy and dysfunction, reactive astrocytosis, synaptic changes, behavioral deficits, and early lethality, demonstrating that intact microglial mitochondria are essential for normal brain maturation. (Mora-Romero et al., 2024)## Roles in Psychiatric Disorders (Depression, Bipolar, Schizophrenia)

Neuroinflammation and microglial activation
Many psychiatric disorders (MDD, BD, schizophrenia, autism) show increased inflammatory responses and microglial activation, with pro-inflammatory (M1) phenotypes contributing to brain pathology and possibly treatment response. (Réus et al., 2015; Hong et al., 2016)Depression, anxiety, ASD, and schizophrenia are all associated with microglial involvement in negative affect, social deficits, compulsive behavior, and fear memory. (Zhu et al., 2023; Brisch et al., 2021)**Mitochondrial dysfunction as an immune–metabolic hub**
In depression and bipolar disorder, mitochondrial abnormalities (impaired oxidative phosphorylation, altered fission/fusion, excess ROS) are linked to enhanced inflammatory responses, neuroprogression, and neuronal vulnerability. (Culmsee et al., 2019; Ogłodek et al., 2026)Mitochondrial dysfunction in peripheral blood cells (e.g., reduced respiration in platelets and PBMCs) is observed in depressed patients and may serve as a biomarker of neuropsychiatric risk, though causality and prognostic value remain unclear. (Culmsee et al., 2019)Across neurodevelopmental and psychiatric conditions, mitochondrial disorders and dysfunction are frequently reported, especially in ASD, but broader systematic links to many diagnoses (e.g., ADHD, schizophrenia, depression, PTSD) are emerging. (Payares et al., 2024)## Microglia–Mitochondria Crosstalk and Stress/Neurodegeneration (Relevance Across Disorders)

Bidirectional amplification of neuroinflammation
Mitochondrial damage releases mitochondrial DAMPs (e.g., mtDNA, mtROS, cardiolipin, ATP) that are sensed by microglial immune receptors, amplifying neuroinflammation. Activated glia then secrete cytokines that further impair mitochondrial metabolism, creating a vicious cycle. (Lin et al., 2022)In chronic neuroinflammation, microglial mitochondrial complex I activity can sustain low-grade activation through reverse electron transport and ROS production; inhibiting complex I dampens microglial neurotoxicity and improves outcomes in a CNS disease model. (Peruzzotti-Jametti et al., 2024)Stress, a major non-genetic risk for depression, disrupts mitophagy, shifts mitochondrial dynamics, and increases mitochondrial mass and depolarization in frontal cortex, while boosting microglial recruitment and mitochondrial content, underscoring how psychological stress reshapes microglial–mitochondrial networks. (Ulecia-Morón et al., 2025)**Microglial mitochondria and neurodegenerative comorbidity**
In Alzheimer's disease, microglial mitochondrial dysfunction (mtDNA damage, ROS, defective mitophagy) promotes microglial activation, neuroinflammation, and neurotoxicity, leading to neuronal loss and network disruption; correcting microglial mitochondrial defects shows therapeutic promise. (Li et al., 2022; Agrawal & Jha, 2020)## Therapeutic and Conceptual Significance

Therapeutic targeting of microglia and mitochondria
Microglia-targeted interventions (e.g., modulating activation states, anti-inflammatory agents, microglia-selective drugs) are being explored for depression, schizophrenia, ASD, and other neuropsychiatric disorders. (Zhu et al., 2023; Réus et al., 2015; Huang et al., 2025)Restoring microglial mitochondrial health—via improving mitochondrial-lysosome crosstalk, fission/fusion balance, mitophagy, or complex I modulation—is a proposed strategy to reduce neuroinflammation and neuronal damage in depression and neurodegeneration. (Zou et al., 2026; Li et al., 2022; Peruzzotti-Jametti et al., 2024)**Conceptual unification across disorders**
Neurodevelopmental disorders, major psychiatric illnesses, neurodegenerative diseases, and addiction share a common theme: **microglia-driven neuroinflammation tightly coupled to mitochondrial dysfunction**, leading to maladaptive circuit remodeling, synaptic pathology, and behavioral symptoms. (Tay et al., 2018; Hong et al., 2016)## Conclusion

Dysregulated microglia and dysfunctional mitochondria form an interconnected axis that influences brain development, immune signaling, and neuronal survival. Across neurodevelopmental, psychiatric, and addiction-related disorders, this axis contributes to chronic neuroinflammation, aberrant synaptic and circuit remodeling, and heightened vulnerability to stress and degeneration. Because of this central role, microglial state and mitochondrial health are increasingly viewed as shared mechanistic hubs and promising therapeutic targets spanning multiple brain disorders.

References

Agrawal, I., & Jha, S. (2020). Mitochondrial Dysfunction and Alzheimer's Disease: Role of Microglia. *Frontiers in Aging Neuroscience, 12*. https://doi.org/10.3389/fnagi.2020.00252

Brisch, R., Wojtylak, S., Saniotis, A., Steiner, J., Gos, T., Kumaratilake, J., Henneberg, M., & Wolf, R. (2021). The role of microglia in neuropsychiatric disorders and suicide. *European Archives of Psychiatry and Clinical Neuroscience, 272*, 929 - 945. https://doi.org/10.1007/s00406-021-01334-z

Culmsee, C., Michels, S., Scheu, S., Arolt, V., Dannlowski, U., & Alferink, J. (2019). Mitochondria, Microglia, and the Immune System—How Are They Linked in Affective Disorders?. *Frontiers in Psychiatry, 9*. https://doi.org/10.3389/fpsyt.2018.00739

Fan, G., J., R., Suo, M., Chen, Y., Zhang, S., Zeng, Y., & Chen, Y. (2023). Microglia Modulate Neurodevelopment in Autism Spectrum Disorder and Schizophrenia. *International Journal of Molecular Sciences, 24*. https://doi.org/10.3390/ijms242417297

He, D., Xu, H., Zhang, H., Tang, R., Lan, Y., Xing, R., Li, S., Christian, E., Hou, Y., Lorello, P. J., Caldarone, B., Ding, J., Nguyen, L., Dionne, D., Thakore, P., Schnell, A., Huh, J. R., Rozenblatt-Rosen, O., Regev, A., & Kuchroo, V. (2021). Disruption of the IL-33-ST2-AKT signaling axis impairs neurodevelopment by inhibiting microglial metabolic adaptation and phagocytic function. *Immunity, 55*, 159 - 173.e9. https://doi.org/10.1016/j.immuni.2021.12.001

Hong, H., Kim, B. S., & Im, H.-I. (2016). Pathophysiological Role of Neuroinflammation in Neurodegenerative Diseases and Psychiatric Disorders. *International Neurourology Journal, 20*, S2 - 7. https://doi.org/10.5213/inj.1632604.302

Huang, H., Luo, Z., Min, J., Luo, W., Zhou, X., & Wang, C. (2025). Targeting Neuroinflammation in Schizophrenia: A comprehensive review of mechanisms and pharmacological interventions.. *International immunopharmacology, 159*, 114910. https://doi.org/10.1016/j.intimp.2025.114910

Li, Y., Xia, X., Wang, Y., & Zheng, J. C. (2022). Mitochondrial dysfunction in microglia: a novel perspective for pathogenesis of Alzheimer's disease. *Journal of Neuroinflammation, 19*. https://doi.org/10.1186/s12974-022-02613-9

Lin, M., Liu, N., Qin, Z.-H., & Wang, Y. (2022). Mitochondrial-derived damage-associated molecular patterns amplify neuroinflammation in neurodegenerative diseases. *Acta Pharmacologica Sinica, 43*, 2439 - 2447. https://doi.org/10.1038/s41401-022-00879-6

Lukens, J., & Eyo, U. B. (2022). Microglia and Neurodevelopmental Disorders. *Annual review of neuroscience, 45*, 425 - 445. https://doi.org/10.1146/annurev-neuro-110920-023056

Meng, J., Zhang, L., & Zhang, Y.-W. (2024). Microglial Dysfunction in Autism Spectrum Disorder. *The Neuroscientist, 30*, 744 - 758. https://doi.org/10.1177/10738584241252576

Mora-Romero, B., Capelo-Carrasco, N., Pérez-Moreno, J. J., Alvarez-Vergara, M. I., Trujillo-Estrada, L., Romero-Molina, C., Martinez-Marquez, E., Morano-Catalan, N., Vizuete, M., López-Barneo, J., Nieto-Gonzalez, J., Garcia-Junco-Clemente, P., Vitorica, J., Gutierrez, A., Macias, D., Rosales-Nieves, A. E., & Pascual, A. (2024). Microglia mitochondrial complex I deficiency during development induces glial dysfunction and early lethality. *Nature Metabolism, 6*, 1479 - 1491. https://doi.org/10.1038/s42255-024-01081-0

Ogłodek, E. A., Vober, J., & Hýža, M. (2026). Molecular and Neuroimaging Correlates of Bipolar Disorder: Linking Inflammation, Mitochondria, and Brain Circuitry. *International Journal of Molecular Sciences, 27*. https://doi.org/10.3390/ijms27031478

Payares, D. P. V., Spooner, L., Vosters, J. A., Domínguez, S., Patrick, L., Harris, A., & Kanungo, S. (2024). A systematic review on the role of mitochondrial dysfunction/disorders in neurodevelopmental disorders and psychiatric/behavioral disorders. *Frontiers in Psychiatry, 15*. https://doi.org/10.3389/fpsyt.2024.1389093

Peruzzotti-Jametti, L., Willis, C., Krzak, G., Hamel, R., Pirvan, L., Ionescu, R.-B., Reisz, J., Prag, H., Garcia-Segura, M. E., Wu, V., Xiang, Y., Barlas, B., Casey, A., Van Den Bosch, A. V. D., Nicaise, A., Roth, L., Bates, G. R., Huang, H., Prasad, P., . . . Pluchino, S. (2024). Mitochondrial complex I activity in microglia sustains neuroinflammation. *Nature, 628*, 195 - 203. https://doi.org/10.1038/s41586-024-07167-9

Réus, G., Réus, G., Fries, G., Stertz, L., Badawy, M., Passos, I., Barichello, T., Kapczinski, F., & Quevedo, J. (2015). The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders.. *Neuroscience, 300*, 141-54. https://doi.org/10.1016/j.neuroscience.2015.05.018

Tay, T. L., Béchade, C., D'Andrea, I., St-Pierre, M.-K., Henry, M. S., Roumier, A., & Tremblay, M. (2018). Microglia Gone Rogue: Impacts on Psychiatric Disorders across the Lifespan. *Frontiers in Molecular Neuroscience, 10*. https://doi.org/10.3389/fnmol.2017.00421

Ulecia-Morón, C., Bris, Á., MacDowell, K. S., Madrigal, J., García-Bueno, B., Leza, J. C., & Caso, J. (2025). Chronic mild stress disrupts mitophagy and mitochondrial status in rat frontal cortex. *Journal of Translational Medicine, 23*. https://doi.org/10.1186/s12967-025-06604-1

Zhu, H., Guan, A., Liu, J., Peng, L., Zhang, Z., & Wang, S. (2023). Noteworthy perspectives on microglia in neuropsychiatric disorders. *Journal of Neuroinflammation, 20*. https://doi.org/10.1186/s12974-023-02901-y

Zou, X., Shi, M., Xiao, X., Lv, X., Yang, M.-Y., Tian, M., Xie, B., Wang, L., Wang, J., & Qin, D. (2026). Focusing on microglial mitochondria-lysosome crosstalk and neuroinflammation underlying depression: from molecular pathways to potential therapeutic interventions. *Frontiers in Immunology, 17*. https://doi.org/10.3389/fimmu.2026.1775841